Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | FRK | P42685 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674382 | 0.88 | CD274 (0.67) | CD274CYP17A1JAK2FYNKDR | |
| SCHEMBL1257965 | 0.85 | DRD2 (0.43) | DRD2FYNACHEADRA1ADRD3 | |
| SCHEMBL1255250 | 0.80 | FLT3 (0.55) | RETKDR | |
| SCHEMBL14674154 | 0.77 | FLT3 (0.52) | RETKDR | |
| SCHEMBL9958722 | 0.77 | SIGMAR1 (0.45) | DRD2FYNACHEADRA1ADRD3 | |
| SCHEMBL1256469 | 0.76 | SIGMAR1 (0.41) | CD274DRD2FYNACHEADRA1A | |
| Hydrochloric Acid SCHEMBL1256889 | 0.75 | DRD2 (0.44) | DRD2MAP4K4FYNACHEADRA1A | |
| SCHEMBL1256817 | 0.74 | RET (0.51) | RETKDR | |
| SCHEMBL1257631 | 0.72 | CD274 (0.63) | CD274CYP17A1JAK2LCKFYN | |
| SCHEMBL15686282 | 0.72 | DRD2 (0.58) | CD274DRD2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | CD274 2612/4885CYP17A1 1971/4885DRD2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.